LONDON and MINNEAPOLIS, Sept. 19, 2023 /PRNewswire/ — Bio-Techne Corporation (NASDAQ: TECH) and Cizzle Biotechnology Holdings plc, the UK-based diagnostics developer, are pleased to announce recent progress evaluating specific monoclonal antibodies for Cizzle’s CIZ1B cancer biomarker. Cizzle has successfully completed an evaluation programme aimed at assessing the feasibility of using…Read More
Cizzle and BioTechne Announce Completion of Evaluation Programme for Detection of CIZ1B Using ProteinSimple Branded Simple Western Platform
